Novartis to buy Avidity Biosciences for $12bn
Deal for specialist in rare diseases is biggest acquisition under chief executive Vas Narasimhan
Related reading
Novartis weighs deal for biotech Avidity to boost drug pipeline
Shares in rare disease biotech surge 26% following approach by Swiss group
Eli Lilly close to buying gene-editing biotech Verve Therapeutics
Drugmaker nears $1.3bn deal in search for experimental medicines
Gilead to buy cancer drug developer Arcellx for up to $7.8bn
Deal comes as pharmaceutical groups rush to acquire smaller biotech firms with proven drug pipelines
Big pharma’s scramble over the patent cliff will be costly
Groups will need to buy mature biotechs to replace revenue lost to generic competitors
Merck nears deal for flu-prevention biotech Cidara
San Diego company’s lead drug is a potential alternative to vaccines for vulnerable patients
Gilead nears up to $2bn deal for autoimmune biotech Ouro Medicines
California-based drugmaker takes advantage of surging share price to strike takeovers after a quiet couple of years